SEC Form 4 · accession 0001193125-26-303600
TENAX THERAPEUTICS, INC. · TENX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Thomas Giordano
Officer — CEO · Director
Period of report
Jul 13, 2026
Accepted (ET)
Jul 14, 2026 · 7:29 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000034956
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 13, 2026 | M | 219 | $3.549 | A | 2,824 | D | |
| Common StockF1 | Jul 13, 2026 | M | 8,500 | $5.94 | A | 11,324 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $3.549 | Jul 13, 2026 | M | 219 | D | — | May 17, 2034 | Common Stock | 219 | 218 | D |
| Stock Option (right to buy) | $5.94 | Jul 13, 2026 | M | 8,500 | D | Dec 10, 2025 | Dec 10, 2034 | Common Stock | 8,500 | 1,241,500 | D |
| Stock Option (right to buy)F3 | $13.30 | holding | — | — | — | — | Jan 9, 2036 | Common Stock | 450,000 | 450,000 | D |
| Stock Option (right to buy)F4 | $5.89 | holding | — | — | — | — | May 16, 2035 | Common Stock | 1,400,000 | 1,400,000 | D |
| Stock Option (right to buy)F5 | $992.00 | holding | — | — | — | — | Jun 9, 2032 | Common Stock | 125 | 125 | D |
| Stock Option (right to buy)F6 | $3,152.00 | holding | — | — | — | — | Jul 6, 2031 | Common Stock | 157 | 157 | D |
Explanation of responses
- F1The aggregate exercise price was paid in cash.
- F2The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment.
- F3The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on January 9, 2027, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
- F4The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
- F5The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.
- F6The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025, subject to the Reporting Person's continued employment.